{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:48:07Z","timestamp":1792003687116,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-026-00877-x","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:47:39Z","timestamp":1783684059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cetuximab combination with cytokine induced killer cells effectively inhibit conjunctival squamous cell carcinoma in vitro"],"prefix":"10.1186","volume":"27","author":[{"given":"Hossein","family":"Aghaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Khakpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Shoae-Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"4","key":"877_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/ICO.0000000000003452","volume":"43","author":"KS Ceylanoglu","year":"2024","unstructured":"Ceylanoglu KS, Eisenberg A, Worden FP, Elner VM, Demirci H. Use of cemiplimab, an immune checkpoint inhibitor for conjunctival intraepithelial neoplasia. Cornea. 2024;43(4):528\u201330. https:\/\/doi.org\/10.1097\/ICO.0000000000003452.","journal-title":"Cornea"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/eye.2011.312","volume":"26","author":"N Di Girolamo","year":"2012","unstructured":"Di Girolamo N. Association of human papillomavirus with pterygia and ocular surface squamous neoplasia development. Eye (London). 2012;26:202\u201311.","journal-title":"Eye (London)"},{"issue":"10","key":"877_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/jnci\/djad119","volume":"115","author":"C Metekoua","year":"2023","unstructured":"Metekoua C, Ruffieux Y, Olago V, Dhokotera T, Egger M, et al. Decreasing incidence of conjunctival squamous cell carcinoma in people with HIV in South Africa. J Natl Cancer Inst. 2023;115(10):1213\u20139. https:\/\/doi.org\/10.1093\/jnci\/djad119.","journal-title":"J Natl Cancer Inst"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.exer.2014.10.015","volume":"129","author":"S Gichuhi","year":"2014","unstructured":"Gichuhi S, Ohnuma S, Sagoo MS, Burton MJ. Pathophysiology of ocular surface squamous neoplasia. Exp Eye Res. 2014;129:172\u201382. https:\/\/doi.org\/10.1016\/j.exer.2014.10.015.","journal-title":"Exp Eye Res"},{"key":"877_CR5","doi-asserted-by":"publisher","unstructured":"Greenfield JA, Cohen AK, Galor A, Chodosh J, Stone D, et al. Ocular surface squamous neoplasia: changes in the standard of care 2003 to 2022. Cornea. 2024;18. https:\/\/doi.org\/10.1097\/ICO.0000000000003461.","DOI":"10.1097\/ICO.0000000000003461"},{"key":"877_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0140-6736(96)91685-2","volume":"347","author":"R Newton","year":"1996","unstructured":"Newton R, Ferlay J, Reeves G. Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. Lancet. 1996;347:1450\u20131.","journal-title":"Lancet"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/ICO.0b013e3182a6ea6c","volume":"32","author":"E Adler","year":"2013","unstructured":"Adler E, Turner JR, Stone DU. Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea. 2013;32:1558\u201361.","journal-title":"Cornea"},{"issue":"13","key":"877_CR8","doi-asserted-by":"publisher","first-page":"1152337","DOI":"10.3389\/fonc.2023.1152337","volume":"5","author":"LF He","year":"2023","unstructured":"He LF, Mou P, Wei RL. Epidemiology and survival outcomes of patients with orbital region non-cutaneous squamous cell carcinoma: a population-based analysis. Front Oncol. 2023;5(13):1152337. https:\/\/doi.org\/10.3389\/fonc.2023.1152337.","journal-title":"Front Oncol"},{"issue":"2","key":"877_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00432-012-1319-7","volume":"139","author":"I Messner","year":"2013","unstructured":"Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol. 2013;139(2):201\u20139. https:\/\/doi.org\/10.1007\/s00432-012-1319-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"103916","DOI":"10.1016\/j.critrevonc.2023.103916","volume":"183","author":"S Bhattacharya","year":"2023","unstructured":"Bhattacharya S. An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer. Crit Rev Oncol Hematol. 2023;183:103916. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103916.","journal-title":"Crit Rev Oncol Hematol"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oraloncology.2015.11.019","volume":"53","author":"MJ Ahn","year":"2016","unstructured":"Ahn MJ, D\u2019Cruz A, Vermorken JB, Chen JP, Chitapanarux I, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoRT: a literature review. Oral Oncol. 2016;53:10\u20136.","journal-title":"Oral Oncol"},{"issue":"10166","key":"877_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, et al. RT plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51\u201360.","journal-title":"Lancet"},{"issue":"2","key":"877_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03605-1","volume":"73","author":"A Sharma","year":"2024","unstructured":"Sharma A, Ren X, Rosato A, Sangiolo D, Wang Z, et al. Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunol Immunother. 2024;73(2):21. https:\/\/doi.org\/10.1007\/s00262-023-03605-1.","journal-title":"Cancer Immunol Immunother"},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413\u201341. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095951.","journal-title":"Annu Rev Immunol"},{"key":"877_CR15","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","volume":"28","author":"RL Ferris","year":"2010","unstructured":"Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"877_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-024-02955-7","volume":"43","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang G, Xu T, Ma J, Wang J, et al. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor. J Exp Clin Cancer Res. 2024;43(1):24. https:\/\/doi.org\/10.1186\/s13046-024-02955-7. PMID: 38245792; PMCID: PMC10799482.","journal-title":"J Exp Clin Cancer Res"},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1167\/iovs.08-1988","volume":"49","author":"J Ng","year":"2008","unstructured":"Ng J, Coroneo MT, Wakefield D, Di Girolamo N. Ultraviolet radiation and the role of matrix metalloproteinases in the pathogenesis of ocular surface squamous neoplasia. Invest Ophthalmol Vis Sci. 2008;49:5295\u2013306.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"877_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CJI.0000000000000179","volume":"40","author":"A Shoae-Hassani","year":"2017","unstructured":"Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, et al. NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells. J Immunother. 2017;40(7):265\u201376. https:\/\/doi.org\/10.1097\/CJI.0000000000000179.","journal-title":"J Immunother"},{"key":"877_CR19","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3389\/fimmu.2017.01486","volume":"8","author":"A Shoae-Hassani","year":"2017","unstructured":"Shoae-Hassani A, Behfar M, Mortazavi-Tabatabaei SA, Ai J, Mohseni R, et al. Natural killer cells from the subcutaneous adipose tissue underexpress the NKp30 and NKp44 in obese persons and are less active against major histocompatibility complex class I non-expressing neoplastic cells. Front Immunol. 2017;8:1486. https:\/\/doi.org\/10.3389\/fimmu.2017.01486.","journal-title":"Front Immunol"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"1410457","DOI":"10.3389\/fimmu.2024.1410457","volume":"15","author":"W Liu","year":"2024","unstructured":"Liu W, Yu J, Sun K, Song Q, Li Y, et al. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity. Front Immunol. 2024;15:1410457. https:\/\/doi.org\/10.3389\/fimmu.2024.1410457.","journal-title":"Front Immunol"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1758-3284-2-5","volume":"2","author":"DJ Liebertz","year":"2010","unstructured":"Liebertz DJ, Lechner MG, Masood R. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010;2:5.","journal-title":"Head Neck Oncol"},{"key":"877_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","volume":"20","author":"Z Liu","year":"2001","unstructured":"Liu Z, Carvajal M, Carraway CA, et al. Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia. Cornea. 2001;20:81\u20135. https:\/\/doi.org\/10.1097\/00003226-200101000-00016.","journal-title":"Cornea"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1242\/jcs.106.1.145","volume":"106","author":"JD Zieske","year":"1993","unstructured":"Zieske JD, Wasson M. Regional variation in distribution of EGF receptor in developing and adult corneal epithelium. J Cell Sci. 1993;106:145\u201352. https:\/\/doi.org\/10.1242\/jcs.106.1.145.","journal-title":"J Cell Sci"},{"key":"877_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","volume":"115","author":"JA Shields","year":"1997","unstructured":"Shields JA. Surgical management of conjunctival tumors: the 1994 Lynn B. McMahan lecture. Arch Ophthalmol. 1997;115:808.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"877_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41433-021-01422-3","volume":"35","author":"R H\u04e7llhumer","year":"2021","unstructured":"H\u04e7llhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: management and outcomes. Eye (Lond). 2021;35(6):1562\u201373.","journal-title":"Eye (Lond)"},{"issue":"5","key":"877_CR26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","volume":"121","author":"AA Nanji","year":"2014","unstructured":"Nanji AA, Moon CS, Galor A, Sein J, Oellers P, et al. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology. 2014;121(5):994\u20131000.","journal-title":"Ophthalmology"},{"key":"877_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/00003226-200005000-00004","volume":"19","author":"S Sudesh","year":"2000","unstructured":"Sudesh S, Rapuano CJ, Cohen EJ, Eagle RC, Laibson PR. Surgical management of ocular surface squamous neoplasms: the experience from a cornea center. Cornea. 2000;19:278\u201383.","journal-title":"Cornea"},{"issue":"2","key":"877_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajo.2013.10.012","volume":"157","author":"J Besley","year":"2014","unstructured":"Besley J, Pappalardo J, Lee GA, Hirst LW, Vincent SJ. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b. Am J Ophthalmol. 2014;157(2):287-e2.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"877_CR29","doi-asserted-by":"publisher","first-page":"e000842","DOI":"10.1136\/bmjophth-2021-000842","volume":"6","author":"OP Alvarez","year":"2021","unstructured":"Alvarez OP, Zein M, Galor A, Karp CL. Management of ocular surface squamous neoplasia: Bowman Club Lecture 2021. BMJ Open Ophthalmol. 2021;6(1):e000842.","journal-title":"BMJ Open Ophthalmol"},{"issue":"15","key":"877_CR30","doi-asserted-by":"publisher","first-page":"11888","DOI":"10.3390\/ijms241511888","volume":"24","author":"JL C\u00edvico-Ortega","year":"2023","unstructured":"C\u00edvico-Ortega JL, Gonz\u00e1lez-Ruiz I, Ramos-Garc\u00eda P, Cruz-Granados D, Samayoa-Descamps V, et al. Prognostic and clinicopathological significance of epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinoma: systematic review and meta-analysis. Int J Mol Sci. 2023;24(15):11888. https:\/\/doi.org\/10.3390\/ijms241511888.","journal-title":"Int J Mol Sci"},{"key":"877_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","volume":"11","author":"B Gruenberger","year":"2010","unstructured":"Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, et al. Cetuximab, gemcitabine, and oxailplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11:1142\u20138.","journal-title":"Lancet Oncol"},{"issue":"5","key":"877_CR32","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-07-2187","volume":"7","author":"X Li","year":"2008","unstructured":"Li X, Lu Y, Liang K, Pan T, Mendelsohn J, et al. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-EGFR monoclonal antibody cetuximab. Mol Cancer Ther. 2008;7(5):1207\u201317.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"877_CR33","first-page":"507","volume":"1","author":"SM Huang","year":"2002","unstructured":"Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after EGFR blockade. Mol Cancer Ther. 2002;1(7):507\u201314.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"877_CR34","doi-asserted-by":"publisher","first-page":"e107165","DOI":"10.1371\/journal.pone.0107165","volume":"9","author":"Y M\u00f6ller","year":"2014","unstructured":"M\u00f6ller Y, Siegemund M, Beyes S, Herr R, Lecis D, et al. EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PLoS One. 2014;9(9):e107165. https:\/\/doi.org\/10.1371\/journal.pone.0107165.","journal-title":"PLoS One"},{"issue":"1","key":"877_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","volume":"30","author":"J Desai","year":"2024","unstructured":"Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30(1):271\u20138. https:\/\/doi.org\/10.1038\/s41591-023-02696-8.","journal-title":"Nat Med"},{"issue":"3","key":"877_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.22.01423","volume":"41","author":"CM Parseghian","year":"2023","unstructured":"Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, et al. Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS\/RAF wild-type colorectal cancer vary by regimen and line of therapy. J Clin Oncol. 2023;41(3):460\u201371. https:\/\/doi.org\/10.1200\/JCO.22.01423.","journal-title":"J Clin Oncol"},{"issue":"12","key":"877_CR37","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1001\/archophthalmol.2012.2515","volume":"130","author":"T El-Sawy","year":"2012","unstructured":"El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608\u201311.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"877_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IIO.0000000000000271","volume":"59","author":"B Esmaeli","year":"2019","unstructured":"Esmaeli B, Sagiv O. Targeted biological drugs and immune check point inhibitors for locally advanced or metastatic cancers of the conjunctiva, eyelid, and orbit. Int Ophthalmol Clin. 2019;59(2):13\u201326.","journal-title":"Int Ophthalmol Clin"},{"issue":"8","key":"877_CR39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00417-012-2008-6","volume":"250","author":"S Tunik","year":"2012","unstructured":"Tunik S, Nergiz Y, Keklikci U, Akkus M. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2012;250(8):1161\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"877_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12886-023-02893-6","volume":"23","author":"H Aghaei","year":"2023","unstructured":"Aghaei H, Kheirkhah A, Alizadeh AM, Es\u2019haghi A, Aliakbar-Navahi R, et al. Local ocular safety of the subconjunctival injection of cetuximab in rabbits. BMC Ophthalmol. 2023;23(1):155.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"877_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s40425-019-0693-y","volume":"7","author":"J Zhang","year":"2019","unstructured":"Zhang J, Larrocha PS, Zhang B, Wainwright D, Dhar P, et al. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1\/PD-L1 blockade therapy. J Immunother Cancer. 2019;7(1):223. https:\/\/doi.org\/10.1186\/s40425-019-0693-y.","journal-title":"J Immunother Cancer"},{"key":"877_CR42","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.4049\/jimmunol.175.12.7819","volume":"175","author":"M Karimi","year":"2005","unstructured":"Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, et al. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+T cells and NK cells. J Immunol. 2005;175:7819\u201328.","journal-title":"J Immunol"},{"issue":"5","key":"877_CR43","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3892\/or.2015.4233","volume":"34","author":"P Ma","year":"2015","unstructured":"Ma P, He Q, Li W, Li X, Han H, et al. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Oncol Rep. 2015;34(5):2567\u201375. https:\/\/doi.org\/10.3892\/or.2015.4233.","journal-title":"Oncol Rep"},{"issue":"8","key":"877_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jcyt.2018.06.003","volume":"20","author":"J Golay","year":"2018","unstructured":"Golay J, Martinelli S, Alzani R, Cribioli S, Albanese C, et al. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. Cytotherapy. 2018;20(8):1077\u201388. https:\/\/doi.org\/10.1016\/j.jcyt.2018.06.003.","journal-title":"Cytotherapy"},{"issue":"8","key":"877_CR45","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1084\/jem.20060514","volume":"203","author":"T Lenac","year":"2006","unstructured":"Lenac T, Budt M, Arapovic J, Hasan M, Zimmermann A, et al. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med. 2006;203(8):1843\u201350. https:\/\/doi.org\/10.1084\/jem.20060514.","journal-title":"J Exp Med"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00877-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00877-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00877-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:05:34Z","timestamp":1792001134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00877-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1186\/s12865-026-00877-x","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethical committee of Iran University of Medical Sciences. Approval number: IR.IUMS.REC.1401.4133. The written informed consent was taken from the patient who donated the tissue.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"93"}}